Breaking on The Street Stocks To Watch Now! CTMX,
Post# of 25327
(Total Views: 79)
Posted On: 05/03/2024 2:31:57 PM
Breaking on The Street Stocks To Watch Now! CTMX, PRSO, IMCC, KAVL, VTAK
https://thestreetreports.com/breaking-on-the-...kavl-vtak/
Investors are eyeing numerous companies lately, and here’s an insight into five of them.
CytomX Therapeutics Inc. (NASDAQ: CTMX), a key player in conditionally activated masked biologic therapeutics, witnessed a remarkable 215% increase in its stock value on May 1. The company gained attention when it revealed its plan to unveil its financial results for the first quarter of 2024 on May 8, 2024, post-market closure. Additionally, CytomX Therapeutics announced that it would provide an update on the CX 904 Phase 1a dose escalation on the same day. A conference call is also scheduled for May 8 at 5 p.m. Eastern Time.
Pesaro Inc. (NASDAQ: PRSO) is a leading player in cutting-edge 60 GHz and 5G mmWave wireless technology, offering a range of solutions including software, IP, chipsets, and antenna modules. The company recently revealed that it will unveil its first fiscal quarter 2024 financial results on May 13, 2024, after the market close. Following this, a conference call featuring Jim Sullivan, the Chief Financial Officer, and Ron Glibbery, the Chief Executive Officer, will commence at 2 p.m. Pacific Time on the same day. The call will delve into the company’s business prospects and financial performance. In a significant move on April 16, Pesaro Inc. announced that Panasonic System Networks R&D Lab Co. Ltd. has adopted its X710 chipset for a new 60GHz WLAN solution. This collaboration is notable given Panasonic’s global prominence in enterprise and consumer technology.
IM Cannabis Corp. (NASDAQ: IMCC) garnered attention on May 1, with its stock surging 29% during the day due to heightened interest. As a prominent medical cannabis firm operating in Germany and Israel, IM Cannabis Corp. announced its upcoming financial results for the first quarter ending March 31, 2024, to be disclosed on May 8, 2024.
Kaival Brands Innovations Group Inc. (NASDAQ: KAVL), the exclusive distributor of Bidi Vapor LLC’s products like the BIDI® Stick for legal-aged nicotine users in the U.S., recently revealed its first-quarter fiscal 2024 financials on March 25. Revenues surged to $3.2 million from the previous year’s $2.5 million, showcasing robust growth. Notably, in 2022, Kaival Brands sealed a significant deal with Phillip Morris Products SA (NYSE: PM) for VEEBA®, a disposable vape product akin to BIDI® Stick, offering diverse global flavors and targeting convenience for legal-aged nicotine consumers. Both firms share a common goal of combating cigarette smoking. Kaival Brands filed a prospectus related to the offer and sale of common stock and warrants.
Catheter Precision Inc. (NYSE American: VTAK) made headlines on May 1 when it appointed Marie-Claude Jacques as its new Chief Commercial Officer. Known for its VIVOTM and LockeT cardiac electrophysiology products, the medical technology firm highlighted Jacques’ role in leading the commercialization team. On April 24, 2024, Catheter Precision reached a significant milestone with a purchase order for LockeT from HCA Healthcare Inc. (NYSE: HCA). This achievement is pivotal, given HCA Healthcare’s position as a top U.S. healthcare services provider with $64 billion in revenue in 2023.
https://thestreetreports.com/breaking-on-the-...kavl-vtak/
Investors are eyeing numerous companies lately, and here’s an insight into five of them.
CytomX Therapeutics Inc. (NASDAQ: CTMX), a key player in conditionally activated masked biologic therapeutics, witnessed a remarkable 215% increase in its stock value on May 1. The company gained attention when it revealed its plan to unveil its financial results for the first quarter of 2024 on May 8, 2024, post-market closure. Additionally, CytomX Therapeutics announced that it would provide an update on the CX 904 Phase 1a dose escalation on the same day. A conference call is also scheduled for May 8 at 5 p.m. Eastern Time.
Pesaro Inc. (NASDAQ: PRSO) is a leading player in cutting-edge 60 GHz and 5G mmWave wireless technology, offering a range of solutions including software, IP, chipsets, and antenna modules. The company recently revealed that it will unveil its first fiscal quarter 2024 financial results on May 13, 2024, after the market close. Following this, a conference call featuring Jim Sullivan, the Chief Financial Officer, and Ron Glibbery, the Chief Executive Officer, will commence at 2 p.m. Pacific Time on the same day. The call will delve into the company’s business prospects and financial performance. In a significant move on April 16, Pesaro Inc. announced that Panasonic System Networks R&D Lab Co. Ltd. has adopted its X710 chipset for a new 60GHz WLAN solution. This collaboration is notable given Panasonic’s global prominence in enterprise and consumer technology.
IM Cannabis Corp. (NASDAQ: IMCC) garnered attention on May 1, with its stock surging 29% during the day due to heightened interest. As a prominent medical cannabis firm operating in Germany and Israel, IM Cannabis Corp. announced its upcoming financial results for the first quarter ending March 31, 2024, to be disclosed on May 8, 2024.
Kaival Brands Innovations Group Inc. (NASDAQ: KAVL), the exclusive distributor of Bidi Vapor LLC’s products like the BIDI® Stick for legal-aged nicotine users in the U.S., recently revealed its first-quarter fiscal 2024 financials on March 25. Revenues surged to $3.2 million from the previous year’s $2.5 million, showcasing robust growth. Notably, in 2022, Kaival Brands sealed a significant deal with Phillip Morris Products SA (NYSE: PM) for VEEBA®, a disposable vape product akin to BIDI® Stick, offering diverse global flavors and targeting convenience for legal-aged nicotine consumers. Both firms share a common goal of combating cigarette smoking. Kaival Brands filed a prospectus related to the offer and sale of common stock and warrants.
Catheter Precision Inc. (NYSE American: VTAK) made headlines on May 1 when it appointed Marie-Claude Jacques as its new Chief Commercial Officer. Known for its VIVOTM and LockeT cardiac electrophysiology products, the medical technology firm highlighted Jacques’ role in leading the commercialization team. On April 24, 2024, Catheter Precision reached a significant milestone with a purchase order for LockeT from HCA Healthcare Inc. (NYSE: HCA). This achievement is pivotal, given HCA Healthcare’s position as a top U.S. healthcare services provider with $64 billion in revenue in 2023.
(0)
(0)Scroll down for more posts ▼